1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SkinBioTherapeutics Plc

SkinBioTherapeutics Plc

SBTX.L
SkinBioTherapeutics PlcGB flagLondon Stock Exchange
8.00
GBp
+0.25
- -
20.73MMarket Cap
SkinBioTherapeutics Plc
SBTX.L
(London Stock Exchange)

Recent

price

8.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.02
Revenue per Share
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
- -
Basic EPS, GAAP
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.02
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
- -
-0.01
-0.02
-0.03
-0.04
-0.06
-0.06
-0.05
Book Value per Share
- -
0.07
0.03
0.03
0.02
0.03
0.01
0.01
- -
0.02
Tangible Book Value per Share
- -
58
119
122
128
147
157
165
186
228
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
5
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-3,631.57
-2,237.77
-244.47
-24.06
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-1
-2
-1
-3
-3
-3
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-3,735.37
-2,146.91
-237.95
-15.01
Profit Margin (%)
- -
4
3
3
2
5
2
1
- -
6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
- -
4
3
4
2
5
2
2
3
9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.11%
217.15%
Free Cash Flow
- -
18.39%
-52.34%
Net Income, GAAP
- -
3.52%
-75.79%
Sales/Revenue/Turnover
- -
- -
283.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
5
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Immutep Limited (IMMP)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)
Axsome Therapeutics, Inc. (AXSM)
AEON Biopharma, Inc. (AEON)
Tetra Bio-Pharma Inc. (TBPMF)
4D pharma plc (DDDD.L)
Business
SkinBioTherapeutics Plc (SBTX.L) develops and commercialises microbiome-based therapeutics and skincare products targeting skin diseases and conditions; its core offerings include SkinBiotix®, a platform featuring bacteriotherapy products such as FlaxSeedSFI for atopic dermatitis treatment, alongside cosmetic and over-the-counter skincare lines like AxisBiotix® for microbiome balance and hydration. The company operates primarily in the biotechnology and personal care sectors, serving dermatology patients, skincare consumers, and healthcare providers through clinical-stage development and commercial distribution. Founded in 2015 and headquartered in York, United Kingdom, it focuses on the UK and European markets with expansion into international dermatology and cosmetics channels. Recent developments include a strategic research collaboration with Croda International Plc announced in 2024 to advance microbiome-based cosmetic ingredients, alongside progression of its Phase II clinical trial for FlaxSeedSFI in mild atopic dermatitis patients, with topline data expected in late 2025; the company also secured additional grant funding from Innovate UK in early 2025 to support platform expansion and completed a successful retail launch of its first OTC skincare product line in the UK during 2024.